Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

被引:46
|
作者
Zortea, Karine [1 ,2 ]
Franco, Viviane C. [1 ,2 ]
Francesconi, Lenise P. [1 ,2 ]
Cereser, Keila M. M. [1 ,2 ]
Lobato, Maria Ines R. [1 ,2 ]
Belmonte-de-Abreu, Paulo S. [1 ,2 ]
机构
[1] Hosp Clin Porto Alegre, Schizophrenia Program, BR-90035903 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Postgrad Program Med Psychiat, BR-90035903 Porto Alegre, RS, Brazil
来源
NUTRIENTS | 2016年 / 8卷 / 02期
关键词
cardiovascular disease; cholesterol; resveratrol; schizophrenia; METAANALYSIS;
D O I
10.3390/nu8020073
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ. Methods and Results: This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%). Conclusion: In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Resveratrol Supplementation Did Not Improve Cognition in Patients with Schizophrenia: Results from a Randomized Clinical Trial
    Zortea, Karine
    Franco, Viviane C.
    Guimaraes, Paula
    Belmonte-de-Abreu, Paulo S.
    FRONTIERS IN PSYCHIATRY, 2016, 7
  • [2] A Cardiovascular Risk Optimization Program in People With Schizophrenia: A Pilot Randomized Controlled Clinical Trial
    Riera-Molist, Nuria
    Assens-Tauste, Montse
    Roura-Poch, Pere
    Guimera-Gallent, Marta
    Santos-Lopez, Josep Manel
    Serra-Millas, Montserrat
    Frau-Rossello, Neus
    Gallego-Pena, Estefania
    Foguet-Boreu, Quinti
    JOURNAL OF PSYCHIATRIC PRACTICE, 2023, 29 (06) : 456 - 468
  • [3] The effects of soymilk plus probiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a randomized clinical trial
    Hasanpour, Azimeh
    Babajafari, Siavash
    Mazloomi, Seyed Mohammad
    Shams, Mesbah
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [4] Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial
    Xuehui Zheng
    Jinghan Hai
    Yuhang Yang
    Chen Zhang
    Xiangping Ma
    Binghui Kong
    Yuan Zhao
    Yang Hu
    Peili Bu
    Yun Ti
    Hypertension Research, 2023, 46 : 1493 - 1503
  • [5] Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial
    Zheng, Xuehui
    Hai, Jinghan
    Yang, Yuhang
    Zhang, Chen
    Ma, Xiangping
    Kong, Binghui
    Zhao, Yuan
    Hu, Yang
    Bu, Peili
    Ti, Yun
    HYPERTENSION RESEARCH, 2023, 46 (06) : 1493 - 1503
  • [6] The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial
    Abdollahi, Shima
    Salehi-Abargouei, Amin
    Toupchian, Omid
    Sheikhha, Mohammad Hasan
    Fallahzadeh, Hossein
    Rahmanian, Masoud
    Tabatabaie, Mahtab
    Mozaffari-Khosravi, Hassan
    PHYTOTHERAPY RESEARCH, 2019, 33 (12) : 3153 - 3162
  • [7] BODY COMPOSITION AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SCHIZOPHRENIA
    Vidovic, B.
    Milovanovic, S.
    Djordjevic, B.
    Sobajic, S.
    Stankovic, I.
    ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 1375 - 1375
  • [8] Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial
    Karimian, Bahareh
    Soleimani, Azam
    Mohammadsharifi, Ghasem
    Heshmat-Ghahdarijani, Kiyan
    Rejali, Laila
    Shafie, Davood
    Amerizadeh, Atefeh
    Sadeghi, Masoumeh
    CARDIOLOGY RESEARCH AND PRACTICE, 2022, 2022
  • [9] Effects of probiotic supplementation on cardiovascular risk factors in hypercholesterolemia: A systematic review and meta-analysis of randomized clinical trial
    Jiang, Jinchi
    Wu, Caie
    Zhang, Chengcheng
    Zhao, Jianxin
    Yu, Leilei
    Zhang, Hao
    Narbad, Arjan
    Chen, Wei
    Zhai, Qixiao
    JOURNAL OF FUNCTIONAL FOODS, 2020, 74
  • [10] Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
    Krivoy, Amir
    Onn, Roy
    Vilner, Yael
    Hochman, Eldar
    Weizman, Shira
    Paz, Amir
    Hess, Shmuel
    Sagy, Roi
    Kimhi-Nesher, Shiri
    Kalter, Ehud
    Friedman, Tal
    Friedman, Zvi
    Bormant, Gil
    Trommer, Sharon
    Valevski, Avi
    Weizman, Abraham
    EBIOMEDICINE, 2017, 26 : 138 - 145